Retrosense Therapeutics, which is working on a treatment for vision loss, has raised $6m from investors including medical diagnostics company Nerveda.
US-based biopharmaceutical company RetroSense Therapeutics closed a $6m series A round yesterday, securing funding from backers including pharmaceutical and diagnostics company Nerveda.
Participants in the round also included Blue Water Angels, SDL Ventures, Tech Coast Angels, and Michigan Economic Development Corporation.
The proceeds will support the completion of preclinical studies for RetroSense’s lead compound, RST-001, which is being developed to treat of retinitis pigmentosa, a genetic condition which causes vision loss and blindness.
Founded in 2009, RetroSense’s technology is based on research conducted at Wayne State University and Massachusetts General Hospital to develop gene therapy approaches to vision restoration. It raised $75,000 in seed funding from undisclosed investors in 2011.
